Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2022
Zai Lab announces Josh Smiley as COO
Zai Lab announced Josh Smiley's appointment as chief operating officer. The article states he would formally assume the role on August 1, 2022, after completing arrangements with his current employer.
2020
Zai Lab and Turning Point Therapeutics enter Repotrectinib licensing agreement
Zai Lab and Turning Point Therapeutics announced a licensing agreement under which Zai Lab will receive exclusive development and commercialization rights for Repotrectinib in Greater China. Turning Point will receive a $25 million upfront cash payment and may receive milestone payments, as well as royalties on annual net sales in the region.
2020
Zai Lab licenses Greater China rights to repotrectinib
Zai Lab and Turning Point Therapeutics entered into a licensing agreement for investigational drug repotrectinib. Zai Lab obtained exclusive development and commercialization rights in Greater China, while Turning Point Therapeutics is to receive an upfront payment and potential milestone payments and royalties.
2020
Zai Lab and Regeneron partner on REGN1979 in Greater China
Zai Lab and Regeneron announced a strategic collaboration to develop and commercialize REGN1979 in mainland China, Hong Kong, Taiwan and Macau. Zai Lab received development and exclusive commercialization rights in the oncology field in those markets; Regeneron will manufacture and supply the product for the region.